Back to News
Market Impact: 0.18
Alzamend Regains Compliance With Nasdaq Equity Requirement
Source: Nasdaq
Regulation & LegislationHealthcare & BiotechCompany Fundamentals
Alzamend Neuro received Nasdaq confirmation that it has regained compliance with the exchange's minimum equity requirement for continued listing. The notice removes an immediate delisting-compliance risk for the clinical-stage biopharmaceutical company, though no financial figures or operating updates were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
ALZN0.45
More News
- Binance seeks to shore up confidence after record $6.3 billion heist
- Why is Alstom stock down 27% today?
- Alstom shares sink 28% after outlook cut on Coradia Max execution issues
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Binance sees outflows stabilising as exchange returns online after $6.3 billion heist
- Apollo launches $11 billion private credit platform, backed by Abu Dhabi